Arthur He
Stock Analyst at HC Wainwright & Co.
(2.15)
# 1,513
Out of 4,415 analysts
34
Total ratings
50%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
7 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PSTX Poseida Therapeutics | Reiterates: Buy | $20 | $2.87 | +596.86% | 9 | May 2, 2024 | |
| HOOK HOOKIPA Pharma | Maintains: Buy | $6.5 → $5 | $0.93 | +437.52% | 5 | Apr 26, 2024 | |
| BCAB BioAtla | Maintains: Buy | $10 → $7 | $3.25 | +115.38% | 5 | Mar 27, 2024 | |
| LVTX LAVA Therapeutics | Reiterates: Buy | $6 | $3.03 | +98.02% | 6 | Mar 21, 2024 | |
| SLDB Solid Biosciences | Reiterates: Buy | $16 | $10.10 | +58.42% | 2 | Mar 14, 2024 | |
| CALT Calliditas Therapeutics AB (publ) | Reiterates: Buy | $50 | $19.00 | +163.13% | 2 | Feb 22, 2024 | |
| ADAG Adagene | Reiterates: Buy | $5 | $2.41 | +107.47% | 5 | Oct 4, 2023 |
Poseida Therapeutics
May 2, 2024
Reiterates: Buy
Price Target: $20
Current: $2.87
Upside: +596.86%
HOOKIPA Pharma
Apr 26, 2024
Maintains: Buy
Price Target: $6.5 → $5
Current: $0.93
Upside: +437.52%
BioAtla
Mar 27, 2024
Maintains: Buy
Price Target: $10 → $7
Current: $3.25
Upside: +115.38%
LAVA Therapeutics
Mar 21, 2024
Reiterates: Buy
Price Target: $6
Current: $3.03
Upside: +98.02%
Solid Biosciences
Mar 14, 2024
Reiterates: Buy
Price Target: $16
Current: $10.10
Upside: +58.42%
Calliditas Therapeutics AB (publ)
Feb 22, 2024
Reiterates: Buy
Price Target: $50
Current: $19.00
Upside: +163.13%
Adagene
Oct 4, 2023
Reiterates: Buy
Price Target: $5
Current: $2.41
Upside: +107.47%